283 related articles for article (PubMed ID: 37686402)
21. Survival outcomes of malignant peripheral nerve sheath tumors (MPNSTs) with and without neurofibromatosis type I (NF1): a meta-analysis.
Lim Z; Gu TY; Tai BC; Puhaindran ME
World J Surg Oncol; 2024 Jan; 22(1):14. PubMed ID: 38191386
[TBL] [Abstract][Full Text] [Related]
22. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.
Jessen WJ; Miller SJ; Jousma E; Wu J; Rizvi TA; Brundage ME; Eaves D; Widemann B; Kim MO; Dombi E; Sabo J; Hardiman Dudley A; Niwa-Kawakita M; Page GP; Giovannini M; Aronow BJ; Cripe TP; Ratner N
J Clin Invest; 2013 Jan; 123(1):340-7. PubMed ID: 23221341
[TBL] [Abstract][Full Text] [Related]
23. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
24. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
[TBL] [Abstract][Full Text] [Related]
25. CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.
Wang J; Calizo A; Zhang L; Pino JC; Lyu Y; Pollard K; Zhang X; Larsson AT; Conniff E; Llosa NJ; Wood DK; Largaespada DA; Moody SE; Gosline SJ; Hirbe AC; Pratilas CA
Sci Adv; 2023 Nov; 9(47):eadg8876. PubMed ID: 38000020
[TBL] [Abstract][Full Text] [Related]
26. Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST.
Lu HC; Eulo V; Apicelli AJ; Pekmezci M; Tao Y; Luo J; Hirbe AC; Dahiya S
Oncotarget; 2018 May; 9(33):23018-23028. PubMed ID: 29796169
[TBL] [Abstract][Full Text] [Related]
27. Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic target.
Farschtschi S; Kluwe L; Park SJ; Oh SJ; Mah N; Mautner VF; Kurtz A
Cancer Immunol Immunother; 2020 Jul; 69(7):1307-1313. PubMed ID: 32193699
[TBL] [Abstract][Full Text] [Related]
28. RRM2 as a novel prognostic and therapeutic target of NF1-associated MPNST.
Chung MH; Aimaier R; Yu Q; Li H; Li Y; Wei C; Gu Y; Wang W; Guo Z; Long M; Li Q; Wang Z
Cell Oncol (Dordr); 2023 Oct; 46(5):1399-1413. PubMed ID: 37086345
[TBL] [Abstract][Full Text] [Related]
29. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
[TBL] [Abstract][Full Text] [Related]
30. Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities.
Creus-Bachiller E; Fernández-Rodríguez J; Magallón-Lorenz M; Ortega-Bertran S; Navas-Rutete S; Romagosa C; Silva TM; Pané M; Estival A; Perez Sidelnikova D; Morell M; Mazuelas H; Carrió M; Lausová T; Reuss D; Gel B; Villanueva A; Serra E; Lázaro C
Mol Oncol; 2024 Apr; 18(4):895-917. PubMed ID: 37798904
[TBL] [Abstract][Full Text] [Related]
31. Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study.
Martin E; Coert JH; Flucke UE; Slooff WM; van de Sande MAJ; van Noesel MM; Grünhagen DJ; Wijnen MHWA; Verhoef C
Pediatr Blood Cancer; 2020 Apr; 67(4):e28138. PubMed ID: 31889416
[TBL] [Abstract][Full Text] [Related]
32. Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.
Sun D; Xie XP; Zhang X; Wang Z; Sait SF; Iyer SV; Chen YJ; Brown R; Laks DR; Chipman ME; Shern JF; Parada LF
Cell Stem Cell; 2021 Aug; 28(8):1397-1410.e4. PubMed ID: 34010628
[TBL] [Abstract][Full Text] [Related]
33. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.
Mautner VF; Asuagbor FA; Dombi E; Fünsterer C; Kluwe L; Wenzel R; Widemann BC; Friedman JM
Neuro Oncol; 2008 Aug; 10(4):593-8. PubMed ID: 18559970
[TBL] [Abstract][Full Text] [Related]
34. MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
Borcherding DC; Amin NV; He K; Zhang X; Lyu Y; Dehner C; Bhatia H; Gothra A; Daud L; Ruminski P; Pratilas CA; Pollard K; Sundby T; Widemann BC; Hirbe AC
Clin Cancer Res; 2023 Apr; 29(8):1592-1604. PubMed ID: 36799629
[TBL] [Abstract][Full Text] [Related]
35. Expression of Ras signaling pathway proteins and developmental factors in peripheral nerve sheath tumors of patients with neurofibromatosis type 1.
Hagel C; Nörnberg LKN; Friedrich RE
Clin Neuropathol; 2023; 42(4):150-160. PubMed ID: 37226590
[TBL] [Abstract][Full Text] [Related]
36. Assessment of H3K27me3 immunohistochemistry and combination of NF1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics.
Sugita S; Aoyama T; Emori M; Kido T; Takenami T; Sakuraba K; Terai K; Sugawara T; Tsujiwaki M; Hasegawa T
Diagn Pathol; 2021 Aug; 16(1):79. PubMed ID: 34461930
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of magnetic resonance imaging-based radiomics characteristics for differentiation of benign and malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
Ristow I; Madesta F; Well L; Shenas F; Wright F; Molwitz I; Farschtschi S; Bannas P; Adam G; Mautner VF; Werner R; Salamon J
Neuro Oncol; 2022 Oct; 24(10):1790-1798. PubMed ID: 35426432
[TBL] [Abstract][Full Text] [Related]
39. Peripheral nerve sheath tumors from patients with neurofibromatosis type 1 do not have the chromosomal translocation t(X;18).
Liew MA; Coffin CM; Fletcher JA; Hang MT; Tanito K; Niimura M; Viskochil D
Pediatr Dev Pathol; 2002; 5(2):165-9. PubMed ID: 11910511
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
